Abgeschlossene Studien
| GBG 64 | E-VITA |
| GBG 76 | EVELYN |
| GBG 51 | LEA |
| GBG 73 | NeoPHOEBE |
| GBG 43 | TABEA |
| GBG 65 | TIFFANY |
| ZORO |
Abgeschlossene Studien
| Neoadjuvante Therapiestudien | GBG 81 | Brightness |
| GBG 68 | GAIN-2 | |
| GBG 89 | GeparNuevo | |
| GBG 84 | GeparOcto | |
| GBG 90 | GeparOla | |
| GBG 88 | GeparX | |
| GBG 54 | MALE | |
| Adjuvante Therapiestudien | GBG 29 | BCP |
| GBG 68 | GAIN-2 | |
| GBG 34 | IBIS-II DCIS | |
| GBG 28 | IBIS-II Prävention | |
| GBG 54 | MALE | |
| GBG 82 | Olympia | |
| GBG 87 | PALLAS | |
| GBG 78 | Penelope | |
| GBG 59 | SOLE | |
| Palliative Therapiestudien | GBG 85 | AURORA |
| GBG 79 | BrainMet | |
| GBG 86 | Desiree | |
| GBG 54 | MALE | |
| Operative Therapiestudien | GBG 75 | Insema |
| GBG 80 | Senszi |
geplante Studien
| GBG 93 | PADMA | Phase - IV - Studie. Palbociclib und endokrine Therapie bei metastasiertem, ER+/Her2- Mammakarzinom im Vergleich zur Chemotherapie. |
